Pyogenic granuloma in children: Treatment with topical imiquimod

Fallah, Haady; Fischer, Gayle; Zagarella, Samuel

doi:10.1111/j.1440-0960.2007.00389.x

Cited by 34 publications

(21 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No sign of recurrence was seen in a 9.6‐month follow‐up, while the cosmetic result was also very satisfactory for the patients, since no scarring was observed . Similar results demonstrating the efficacy of 5% imiquimod cream with similar application schedules are also to be found on case reports and case series . An example of our own experience with the use of topical 5% imiquimod cream can be seen on a PG on the leg of an 11‐year‐old patient in Figures and .…”

Section: Resultssupporting

confidence: 73%

Therapeutic approaches to pyogenic granuloma: an updated review

Plachouri

Georgiou

2018

Int J Dermatology

View full text Add to dashboard Cite

Pyogenic granuloma is a benign vascular proliferation of the skin and mucous membranes, whose pathogenesis is not fully understood. Despite its benign nature, it can have a significant negative impact on patients’ quality of life, and therefore appropriate therapy is needed. Over the years, a lot of therapeutic modalities have been used in order to successfully treat this condition. This paper is an updated systematic overview of all the reported successful treatments described in the literature and was conducted according to the PRISMA guidelines for systematic reviews. Articles derived from the databases PubMed, EMBASE, and SCOPUS, published between 1981 and 2018, were analyzed for this study. In the literature, there are several studies, case series, and case reports that demonstrate encouraging results with the use of various methods, such as surgical intervention or laser treatment, but also with more conservative approaches, including the application of topical and systemic agents. The selection of the appropriate treatment should be made individually, depending on severity of the disease and patient characteristics. Both research efforts as well as clinical reporting are necessary in order to provide more insight on the management of these vascular tumors. This paper aims to provide a summarized update on the reported therapies and to raise awareness for the need to conduct larger systematic studies in order to adequately evaluate and compare the effectiveness of the presented therapeutic strategies.

show abstract

Section: Resultssupporting

confidence: 73%

Therapeutic approaches to pyogenic granuloma: an updated review

Plachouri

Georgiou

2018

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…Even if clinical characteristics combined with a history of a fast growing, easily bleeding lesions are quite often sufficient to distinguish a PG, up to 18% of this kind of lesions are misdiagnosed or confused with other diseases (spiz naevus, true hemangiomas, amelanotic melanoma, Kaposi sarcoma, common warts, squamous cell carcinoma and spindle cell tumors) [9]. A medical therapy, consisting in topical Imiquimod application, has been recently proposed with optimal results; Fallah et al [10] treated 5 children with facial PG using topic Imiquimod 5% cream. In all cases, resolution of the lesion was achieved in 2 14 weeks without recurrences after median follow up 2.3 months.…”

Section: Resultsmentioning

confidence: 99%

Multiple pyogenic granuloma of the penis in a four-year-old child: a case report

Spinelli

Giacomo

Bertocchini

et al. 2009

Cases J

View full text Add to dashboard Cite

Pyogenic granulomas are common, acquired, benign vascular lesions of the skin and mucous membranes that can develop both spontaneously and traumatically. We present a unique case of a four-year healthy, uncircumcised boy with multiple pyogenic granuloma on the mucous face of the penis foreskin. Although penile multiple pyogenic granulomas have previously been described in adults, there are no reports of similar problems in children. In this patient, the pathogenesis of the lesions is probably trauma related as reported in the anamnesis. Therapeutic options are discussed.

show abstract

“…4 It has been used successfully in the treatment of infantile hemangiomas and pyogenic granulomas with its antiangiogenic activity. [5][6][7] In a prospective, open-label, single center, phase II clinical trial, imiquimod cream was applied under occlusion 3 times a week for 24 weeks in 17 immunocompetent Kaposi patients. Half of the patients showed a marked improvement and complete remission was achieved in 2 cases.…”

Section: 23mentioning

confidence: 99%

Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma

Gündüz¹,

Günay²,

İnanır³

et al. 2012

J Dermatol Case Rep

View full text Add to dashboard Cite

Background: The classic Kaposi sarcoma is most common in the Mediterranean population over 50 years of age and presents with reddish-brown papules and nodules particularly on the lower limbs. Treatment depends on the clinical presentation and extension of lesions. Imiquimod is as an immune response modifier with antiangiogenic activity. Main observations:We present a 74-year-old man with classic Kaposi sarcoma who had multiple, small, violaceous papules and nodules on the trunk and extremities with a history of 14 years. He complained particularly from plantar hyperkeratotic painful nodules. Treatment with imiquimod 5% cream under occlusion resulted with almost complete regression within 12 weeks. No local or systemic side effects were observed. Conclusions:Topical imiquimod was a safe and effective therapy in our patient with

show abstract

Pyogenic granuloma in children: Treatment with topical imiquimod

Cited by 34 publications

References 9 publications

Therapeutic approaches to pyogenic granuloma: an updated review

Therapeutic approaches to pyogenic granuloma: an updated review

Multiple pyogenic granuloma of the penis in a four-year-old child: a case report

Efficacy of 5% imiquimod cream in a patient with classic Kaposi sarcoma

Contact Info

Product

Resources

About